Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-e7ba6957dcf929fb2c43dcd1b448488d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-e7ba6957dcf929fb2c43dcd1b448488d"/>
<resource>
<Composition>
<id value="composition-en-e7ba6957dcf929fb2c43dcd1b448488d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-e7ba6957dcf929fb2c43dcd1b448488d"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-e7ba6957dcf929fb2c43dcd1b448488d</b></p><a name="composition-en-e7ba6957dcf929fb2c43dcd1b448488d"> </a><a name="hccomposition-en-e7ba6957dcf929fb2c43dcd1b448488d"> </a><a name="composition-en-e7ba6957dcf929fb2c43dcd1b448488d-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/397/002</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - siklos</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/397/002"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpe7ba6957dcf929fb2c43dcd1b448488d"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - siklos"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Siklos is and what it is used for</li><li>What you need to know before you take Siklos</li><li>How to take Siklos</li><li>Possible side effects</li><li>How to store Siklos</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What siklos is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What siklos is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Siklos is used to prevent painful crises, including sudden chest pain, caused by sickle cell disease, in adults, adolescents and children older than 2 years.</p><p>Sickle cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood.<br/>Some cells become abnormal, rigid and take a crescent or sickle shape which leads to anemia. The sickle cells also get stuck in blood vessels, blocking blood flow. This can cause acute pain crises and organ damage.</p><p>For severe painful crises, most patients require hospitalisation. Siklos will decrease the number of painful crises as well as the need for hospitalisation linked with the disease.</p><p>The active substance of Siklos, hydroxycarbamide, is a substance which inhibits growth and proliferation of some cells, such as blood cells. These effects lead to a reduction of circulating red, white and coagulation blood cells (myelosuppressive effect). In sickle cell disease, hydroxycarbamide helps also to prevent red blood cells from taking abnormal shape.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take siklos"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take siklos"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Siklos</p><ul><li>if you are allergic to hydroxycarbamide or any of the other ingredients of this medicine (listed in section 6),</li><li>if you suffer from severe liver disease,</li><li>if you suffer from severe kidney disease,</li><li>if you are myelosuppressed (if you have decreased production of red, white, or coagulating blood cells) as described in section 3 How to take Siklos, Treatment follow-up ,</li><li>if you are breast-feeding (see section Pregnancy, breast-feeding and fertility ).</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist or nurse before taking Siklos</p><ul><li>if you have a liver disease,</li><li>if you have a kidney disease,</li><li>if you have leg ulcers,</li><li>if you are taking other myelosuppressive medicines (decrease production of red, white, or coagulating blood cells) or receiving radiation therapy,</li><li>if you have a known lack of vitamin B12 or folate.</li></ul><p>If you experience (or have experienced) any of the above, please tell your doctor. If you have any question, please ask your doctor or pharmacist or nurse.</p><p>Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicine, their monitoring and care.</p><p>Other medicines and Siklos</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Information sharing is especially required for</p><ul><li>some antiretroviral medicines (those that inhibit or destroy a retrovirus such as HIV), e.g. didanosine, stavudine and indinavir (a drop in your white cell count may occur),</li><li>myelosuppressive medicines (those that decrease production of red, white, or coagulating blood cells) and radiation therapy,</li><li>some vaccines.</li></ul><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Siklos is not recommended during pregnancy. Please contact your doctor immediately if you think you may be pregnant. The use of effective contraception is strongly recommended.</p><p>If you become pregnant or plan to become pregnant while taking Siklos, your doctor will discuss with you the potential benefits and risks of continuing using Siklos.</p><p>For male patients taking Siklos, if your partner becomes pregnant or plans to become pregnant, your doctor will discuss with you the potential benefits and risks of continuing using Siklos.</p><p>The active substance of Siklos passes into human breast-milk. You must not breast-feed while taking Siklos.</p><p>Hydroxycarbamide may decrease sperm production in male patients while they are being treated.</p><p>Driving and using machines</p><p>Some people may experience dizziness when using Siklos. Do not drive or use any tools or machines if you experience dizziness whilst taking Siklos.</p></div>
</text>
</section>
<section>
<title value="3. How to take siklos"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take siklos"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take Siklos exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Dose</p><p>Your doctor will tell you how much of Siklos to take each day and will describe the dose in whole, half or quarter tablets.</p><p>The prescribed dose of Siklos must be taken once daily, preferably in the morning before breakfast.<br/>It can be taken with a glass of water or a very small amount of food. If you cannot swallow the tablets, you can disintegrate them in water immediately before use: Place the required dose (preferably broken if Siklos 1 000 mg tablet is used) in a teaspoon and add some water. As soon as the tablet is disintegrated, swallow the content of the teaspoon. You can add a drop of syrup or mix the content with food to mask a possible bitter taste. Then drink a large glass of water or any other drink.</p><p>Handling</p><p>Siklos is a cytotoxic medicine that must be handled with care. Any person, in particular pregnant women, who are not taking Siklos should avoid direct contact with the parts when breaking a tablet. Wash your hands before and after contact with the tablets. In case the prescribed dose requires breaking the tablet in halves or quarters, this should be done out of the reach of food. Powder spilled from the broken tablet should be wiped up with a damp disposable towel which must be thrown out. For the storage of unused broken tablets, see section 5 How to store Siklos .</p><p>Treatment follow-up</p><p>Your doctor will tell you how long to take Siklos.</p><p>When taking Siklos you will have regular blood tests and check your liver and kidney. Depending on the dose you take, these tests may be performed monthly or every two months.</p><p>Depending on these results your doctor will adjust your dose of Siklos.</p><p>If you take more Siklos than you should</p><p>If you take more Siklos than you should or if a child has taken any, contact your doctor or the nearest hospital immediately as you may need urgent medical treatment. The most common symptoms of overdose with Siklos are:</p><ul><li>Redness of the skin,</li><li>Soreness (touch is painful) and swelling of the palms of hands and soles of feet followed by the hands and feet becoming scaly,</li><li>Skin becoming strongly pigmented (locally changes of colour),</li><li>Soreness or swelling in the mouth.</li></ul><p>If you forget to take Siklos</p><p>Do not take a double dose to make up for a forgotten tablet. Continue as normal when it is time to take the next dose as prescribed by your doctor.</p><p>If you stop taking Siklos</p><p>Do not stop your treatment unless advised by your doctor. If you have any further question on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, Siklos can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you notice any of the following serious side effects:</p><ul><li>A severe infection,</li><li>Tiredness and/or looking pale,</li><li>Unexplained bruising (accumulation of blood under the skin) or bleeding,</li><li>Unusual headache,</li><li>Difficulties in breathing.</li></ul><p>Tell your doctor as soon as possible if you notice any of the following side effects:</p><ul><li>Fever or chills,</li><li>Feeling sick, or a general feeling of being unwell,</li><li>Rash (itching red eruption of the skin),</li><li>Ulcers or wounds on your legs,</li><li>Sore (open skin infection) on your skin,</li><li>Disorientation (confusion) and dizziness.</li></ul><p>DETAILS OF SIDE EFFECTS</p><p>Very common side effects (may affect more than 1 in 10 people): Low blood cell counts (myelosuppression), enlargement of red blood cells,<br/>Absence or low amount of sperm in the semen (azoospermia or oligospermia). Siklos may hence decrease the ability of men to father children.</p><p>Common side effects (may affect up to 1 in 10 people): Reduced number of red blood cells (anaemia), low platelet count, headache, skin reactions, inflammation or ulceration of the mouth (oral mucositis).</p><p>Uncommon side effects (may affect up to 1 in 100 people): Dizziness, nausea, itching red eruption of the skin (rash), black nails (melanonychia), and hair loss.</p><p>Rare side effects (may affect up to 1 in 1 000 people): Wounds on the legs (leg ulcers), and modification of liver function.</p><p>Very rare side effects (may affect up to 1 in 10 000 people) or unknown frequency (frequency cannot be estimated from the available data): Inflammation of the skin causing red scaly patches and possibly occurring together with pain in the joints.</p><p>Isolated cases of malignant disease of blood cells (leukaemia), skin cancer in elderly patients, bleeding, gastrointestinal disturbances, vomiting, skin dryness, fever, absence of menstrual cycles (amenorrhoea), and weight gain.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store siklos"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store siklos"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use Siklos after the expiry date which is stated on the carton and the bottle after EXP.<br/>Store below 30 C.</p><p>Unused broken tablets must be replaced in the bottle and must be used within three months.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Siklos contains</p><ul><li><p>The active substance is hydroxycarbamide.<br/>Each Siklos 100 mg film-coated tablet contains 100 mg hydroxycarbamide. Each Siklos 1 000 mg film-coated tablet contains 1 000 mg hydroxycarbamide.</p></li><li><p>The other ingredients are sodium stearyl fumarate, silicified microcrystalline cellulose and basic butylated methacrylate copolymer.</p></li></ul><p>What Siklos looks like and contents of the pack</p><p>Siklos 100 mg film-coated tablets are off-white, oblong-shaped tablets with a break line on both sides. The tablet can be divided into two equal parts. Each half of tablet is embossed H on one side. Siklos 100 mg is supplied in plastic bottles containing 60, 90 or 120 tablets.</p><p>Siklos 1 000 mg film-coated tablets are off-white, capsule-shaped tablets marked with three score lines on both sides. The tablet can be divided into four equal parts. Each quarter of tablet is embossed T on one side. Siklos 1 000 mg is supplied in plastic bottles containing 30 tablets.</p><p>All pack sizes may not be marketed.</p><p>Marketing Authorisation Holder THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine France</p><p>Manufacturer Delpharm Lille Parc d Activit s Roubaix-Est 22 rue de Toufflers CS 5059452 Lys-lez-Lannoy France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien THERAVIA T l/Tel: +32(0) 40 11 Lietuva THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Pranc zija Tel: +33 (0)1 72 69 01<br/>THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine -<br/>Tel: +33 (0)1 72 69 01 Luxembourg/Luxemburg THERAVIA T l/Tel: +352 27 86 23 esk republika THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Francie Tel: +33 (0)1 72 69 01 Magyarorsz g THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Franciaorsz g Tel.: +33 (0)1 72 69 01 Danmark resund Pharma ApS<br/>Dronningens Tv rgade 9<br/>1302 K benhavn K Danmark Tlf: +45 53 63 39 Malta THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Franza Tel: +33 (0)1 72 69 01 Deutschland THERAVIA Tel: +49 (0)8 00 10 90 Nederland THERAVIA Tel: +31 (0)2 07 03 81 Eesti THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Prantsusmaa Tel: +33 (0)1 72 69 01 Norge resund Pharma ApS<br/>Dronningens Tv rgade 9<br/>1302 K benhavn K Danmark Tlf: +45 53 63 39<br/>DEMO ABEE : +30 210 81 61 sterreich THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Frankreich Tel: +33 (0)1 72 69 01 Espa a Abacus Medicine A/S<br/>Tel: +34 910605Polska THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Francja Tel: +33 (0)1 72 69 01 France THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine Tel: +33 (0)1 72 69 01 Portugal Abacus Medicine A/S<br/>Tel: +34 910605Hrvatska THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine<br/>Tel: +33 (0)1 72 69 01 Rom nia THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Fran a Tel: +33 (0)1 72 69 01 Ireland THERAVIA Tel: +353(0)1 69 50 Slovenija THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Francija Tel: +33 (0)1 72 69 01 sland THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Frakkland S mi: +33 (0)1 72 69 01 Slovensk republika THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Franc zsko Tel: +33 (0)1 72 69 01 Italia THERAVIA Tel: +39 80 09 59 Suomi/Finland resund Pharma ApS Dronningens Tvaergade 9 1302 K penhamina K Tanska Puh/Tel: +45 53 63 39<br/>The Star Medicines Importers Co Ltd : +357 25 37 1Sverige resund Pharma ApS Dronningens Tvaergade 9 1302 K penhamn K Danmark Tel: +45 53 63 39 Latvija THERAVIA 16 Rue Montrosier<br/>92200 Neuilly-sur-Seine - Francija Tel: +33 (0)1 72 69 01 United Kingdom (Northern Ireland) THERAVIA Tel: +44-(0)203-695 9This leaflet was last revised in MM/YYYY.</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpe7ba6957dcf929fb2c43dcd1b448488d"/>
<resource>
<MedicinalProductDefinition>
<id value="mpe7ba6957dcf929fb2c43dcd1b448488d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpe7ba6957dcf929fb2c43dcd1b448488d"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpe7ba6957dcf929fb2c43dcd1b448488d</b></p><a name="mpe7ba6957dcf929fb2c43dcd1b448488d"> </a><a name="hcmpe7ba6957dcf929fb2c43dcd1b448488d"> </a><a name="mpe7ba6957dcf929fb2c43dcd1b448488d-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/397/002</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Siklos 100 mg film-coated tablet.</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/397/002"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Siklos 100 mg film-coated tablet."/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
